---
title: "Pulmatrix | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286564231.md"
datetime: "2026-05-15T12:22:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286564231.md)
  - [en](https://longbridge.com/en/news/286564231.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286564231.md)
---

# Pulmatrix | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.32.

EBIT: As of FY2026 Q1, the actual value is USD -1.304 M.

### First Quarter 2026 Financial Results

#### Operating Expenses

-   **Research and Development Expenses**: Pulmatrix, Inc.’s research and development expenses were $3 thousand for the three months ended March 31, 2026, compared to $19 thousand for the three months ended March 31, 2025. All clinical development is currently on hold as the Company works to license or monetize its clinical assets .
-   **General and Administrative Expenses**: General and administrative expenses decreased by approximately $0.5 million to $1,289 thousand for the three months ended March 31, 2026, from $1,828 thousand for the three months ended March 31, 2025 . This decrease was primarily due to higher costs incurred in the prior year period related to the preparation and filing of a registration statement on Form S-4 .
-   **Total Operating Expenses**: Total operating expenses were $1,292 thousand for the three months ended March 31, 2026, down from $1,847 thousand for the same period in 2025 .

#### Operating Profit / Loss

-   **Loss from Operations**: The loss from operations was -$1,292 thousand for the three months ended March 31, 2026, compared to -$1,847 thousand for the three months ended March 31, 2025 .

#### Other Income (Expense)

-   **Interest Income**: Interest income was $12 thousand for the three months ended March 31, 2026, compared to $53 thousand for the same period in 2025 .
-   **Fair Value Adjustment of Warrants**: There was no fair value adjustment of warrants for the three months ended March 31, 2026, compared to $66 thousand for the same period in 2025 .
-   **Other Income (Expense), Net**: Other income (expense), net, was $108 thousand for the three months ended March 31, 2026, compared to -$80 thousand for the same period in 2025 .
-   **Total Other Income (Expense), Net**: Total other income (expense), net, was $120 thousand for the three months ended March 31, 2026, compared to $39 thousand for the same period in 2025 .

#### Net Loss

-   **Net Loss**: The net loss for the three months ended March 31, 2026, was -$1,172 thousand, an improvement from a net loss of -$1,808 thousand for the three months ended March 31, 2025 .

#### Cash and Cash Equivalents

-   **Cash and Cash Equivalents Balance**: As of March 31, 2026, Pulmatrix, Inc.’s total cash and cash equivalents balance was $3,324 thousand, down from $4,088 thousand as of December 31, 2025 .
-   **Current Restricted Cash**: Current restricted cash was $700 thousand as of March 31, 2026, compared to $0 as of December 31, 2025 .
-   **Long-term Restricted Cash**: Long-term restricted cash was $7 thousand as of March 31, 2026, compared to $10 thousand as of December 31, 2025 .

#### Assets

-   **Prepaid Expenses and Other Current Assets**: Prepaid expenses and other current assets were $465 thousand as of March 31, 2026, compared to $41 thousand as of December 31, 2025 .
-   **Total Current Assets**: Total current assets amounted to $4,489 thousand as of March 31, 2026, compared to $4,129 thousand as of December 31, 2025 .
-   **Total Assets**: Total assets were $4,496 thousand as of March 31, 2026, compared to $4,139 thousand as of December 31, 2025 .

#### Liabilities

-   **Accounts Payable**: Accounts payable increased to $651 thousand as of March 31, 2026, from $272 thousand as of December 31, 2025 .
-   **Accrued Expenses and Other Current Liabilities**: Accrued expenses and other current liabilities were $254 thousand as of March 31, 2026, compared to $57 thousand as of December 31, 2025 .
-   **Total Current Liabilities**: Total current liabilities were $905 thousand as of March 31, 2026, compared to $329 thousand as of December 31, 2025 .
-   **Total Liabilities**: Total liabilities were $905 thousand as of March 31, 2026, compared to $329 thousand as of December 31, 2025 .

#### Stockholders’ Equity

-   **Total Stockholders’ Equity**: Total stockholders’ equity was $3,591 thousand as of March 31, 2026, compared to $3,810 thousand as of December 31, 2025 .

#### Outlook / Guidance

Pulmatrix, Inc. anticipates its proposed merger with Eos SENOLYTIX to close in the third quarter of 2026, subject to customary closing conditions . The Company believes its current cash position is sufficient to fund operations at least through the anticipated closing of this merger .

### Related Stocks

- [PULM.US](https://longbridge.com/en/quote/PULM.US.md)

## Related News & Research

- [Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger | PULM Stock News](https://longbridge.com/en/news/295797452.md)
- [Can Gold Make a New High in 2026?](https://longbridge.com/en/news/295569739.md)
- [ESS Tech reschedules Q2 2026 results conference call to Tuesday evening](https://longbridge.com/en/news/295407778.md)
- [VerifyMe extends merger agreement outside date to Oct. 31, 2026](https://longbridge.com/en/news/295698903.md)
- [Illinois Tool Works declares Q3 2026 dividend of R$ 1.48 per unit](https://longbridge.com/en/news/295435249.md)